Neuren Pharmaceuticals Limited
NURPF
$10.97
-$1.31-10.67%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 11.77% | 14.38% | -61.86% | -62.80% | 1,050.75% |
| Total Other Revenue | 21,161.82% | 21,371.43% | -- | -- | -98.06% |
| Total Revenue | 13.88% | 16.55% | -61.86% | -62.80% | 986.35% |
| Cost of Revenue | 0.45% | 2.80% | 50.33% | 46.62% | 83.61% |
| Gross Profit | 15.19% | 17.89% | -87.59% | -87.90% | 1,986.26% |
| SG&A Expenses | -19.82% | -17.95% | -23.06% | -24.96% | 304.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.84% | -0.57% | 35.22% | 31.88% | 101.45% |
| Operating Income | 15.87% | 18.57% | -91.67% | -91.88% | 2,166.91% |
| Income Before Tax | 10.01% | 12.58% | -76.46% | -77.04% | 2,029.16% |
| Income Tax Expenses | -19.84% | -17.97% | 107.78% | 102.64% | -- |
| Earnings from Continuing Operations | 22.64% | 25.50% | -83.46% | -83.87% | 1,396.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.64% | 25.50% | -83.46% | -83.87% | 1,396.08% |
| EBIT | 15.87% | 18.57% | -91.67% | -91.88% | 2,166.91% |
| EBITDA | 15.87% | 18.57% | -91.65% | -91.86% | 2,165.09% |
| EPS Basic | 22.58% | 25.47% | -83.62% | -84.07% | 1,374.07% |
| Normalized Basic EPS | 9.97% | 12.53% | -76.71% | -77.23% | 2,000.00% |
| EPS Diluted | 23.34% | 26.20% | -83.55% | -83.92% | 1,412.85% |
| Normalized Diluted EPS | 10.63% | 13.22% | -76.66% | -77.18% | 2,031.86% |
| Average Basic Shares Outstanding | 0.05% | 0.05% | 1.06% | 1.06% | 1.46% |
| Average Diluted Shares Outstanding | -0.57% | -0.57% | 0.59% | 0.59% | -0.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |